Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02488330
- Locations
- 🇫🇷
Hopital Roger Salengro, Lille, France
🇯🇵National Hospital Organization Shikoku Cancer Center, Ehime, Japan
🇮🇹Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino, Torino, Piemonte, Italy
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1280
- Registration Number
- NCT02486718
- Locations
- 🇪🇸
Hospital NisA 9 de Octubre, Valencia, Spain
🇨🇳Zhejiang Cancer Hospital, Zhejiang, China
🇫🇷Hôpital Universitaire Dupuytren, Limoges, France
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
- Conditions
- Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 154
- Registration Number
- NCT02486952
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Choroidal Neovascularization
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 273
- Registration Number
- NCT02484690
- Locations
- 🇺🇸
Retina Consultants, San Diego, Poway, California, United States
🇺🇸New England Retina Associates, Hamden, Connecticut, United States
🇺🇸Austin Retina Associates, Austin, Texas, United States
Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency of Depression in Rheumatoid Arthritis (RA) Participants
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1292
- Registration Number
- NCT02485483
A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02484703
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Emory University School of Medicine; Department of Human Genetics & Pediatrics, Decatur, Georgia, United States
🇺🇸Duke Clin Rsch Institute, Durham, North Carolina, United States
A Study of Pertuzumab in Participants With Prostate Cancer
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT02480010
Safety of Xeloda in Solid Tumours
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1268
- Registration Number
- NCT02479217
A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Conditions
- Geographic Atrophy
- Interventions
- Other: No intervention
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 296
- Registration Number
- NCT02479386
- Locations
- 🇵🇱
Klinika Okulistyki Ogolnej w Lublinie, Lublin, Poland
🇵🇱SPEKTRUM Osrodek Okulistyki Klinicznej, Wroclaw, Poland
🇺🇸Northwest Arkansas Retina Associates, Springdale, Arkansas, United States
A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
- Conditions
- Hemophilia A
- Interventions
- Drug: FVIII ReplacementDrug: Bypassing Agents
- First Posted Date
- 2015-06-22
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT02476942
- Locations
- 🇺🇸
University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States
🇺🇸Santa Monica Oncology Center, Santa Monica, California, United States
🇺🇸Georgetown Uni Medical Center; Lombardi Cancer Center, Washington, D.C., District of Columbia, United States